Moderna shares rise after company unveils single-injection vaccine booster for Covid and influenza

Moderna shares rise after company unveils single-injection vaccine booster for Covid and influenza

Anjali Sundararaman, a nursing student at San Francisco State University, administers a modern COVID-19 vaccine at the Qxiao Zoo during a vaccination clinic at the Southeastern Health Center of the Bayview-Hunters Point neighborhood on Monday February in San Francisco, California. administers the dosage. 8, 2021.

Stephen Lam | Chronicle of San Francisco | Hearst Diary via Getty Images

Moderna’s shares rose on Thursday when it announced it was developing a two-in-one booster vaccine that protects against both COVID-19 and seasonal flu.

According to a press release, the new vaccine, which the company calls mRNA-1073, combines Moderna’s current COVID vaccine with the flu vaccine, which is in development. Moderna shares jumped more than 5% after the announcement.

“Today we are announcing the first step of our new respiratory vaccine program with the development of a single dose vaccine that is a COVID-19 booster and an influenza booster,” CEO Stefan Bansel said in a press release Thursday. connects. “We are making progress in recruiting patients into our rare disease programs and are fully enrolled in our personalized cancer vaccine trial. We believe this is the start of a new era in information-based medicine. East.”

The announcement follows Moderna’s highly successful launch of its two-dose mRNA-based COVID vaccine, which was cleared for emergency use by the Food and Drug Administration in December. According to data compiled by the Centers for Disease Control and Prevention, more than 147 million shots of Moderna have been administered in the United States.

Messenger RNA, or mRNA, technology has been in development for years, but Moderna and Pfizer’s vaccines mark the first time that mRNA has been approved for use in humans. The mRNA-based COVID vaccines work by tricking the body to produce a harmless piece of the virus, which triggers an immune response. It is said to be easier to produce than conventional vaccines, which typically use a dead or weakened virus to induce an immune response.

Bansal had said earlier that the company hopes to have a booster that combines protection against the two viruses.

“What we’re trying to do at Moderna is actually get the flu shot at the clinic this year and then match our flu shot with our COVID shot so you only get just one push to your local CVS store every year. So… it’ll save you the kind of anxiety from the covid strain and the seasonal flu, ”Bansal said in April.

Moderna also announced Thursday that it is developing a pediatric vaccine, called mRNA-1365, which will combine vaccines against respiratory syncytial virus and human metapneumovirus.

– CNBC’s Kevin Stankiewicz contributed reporting



Please enter your comment!
Please enter your name here